Babson Diagnostics Wins Austin A-List Award

AUSTIN, TEXAS, May 23, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, was named a winner at the Greater Austin Chamber of Commerce’s 2019 Austin A-List Awards, “Austin’s premiere honor for homegrown companies.” The A-List honors 24 local companies in various stages of growth that demonstrate cutting-edge innovation, achievable goals, sustainable practices, scalability, and leadership.

“Each nominee and winner represent what makes Austin’s innovative and entrepreneurial community unique and successful. We look forward to a yearlong celebration and relationship with our winners and thank all 165 nominees for everything they do for our community and economy,” said Austin Chamber Senior Vice President, Global Technology and Innovation, Leigh Christie.

The annual A-List Awards contribute to Austin’s reputation as a hub for rapid technological and economic growth. The Greater Austin Chamber of Commerce was recently awarded the 2019 Mac Conway Award, signifying its status as one of the top economic development organizations in the nation.

Eric Olson, CEO of Babson Diagnostics, observed: “Austin is a very special place. Its focus on innovation is what motivated us to relocate from New York and open our headquarters here. To be honored just two years later as an innovative homegrown company is quite an experience. We want to thank the Austin Chamber of Commerce, SXSW, and the City of Austin for welcoming us so warmly. We hope to make our city proud.”

Babson Diagnostics Welcomes Mini Kahlon to its Board of Directors

AUSTIN, TEXAS, May 14, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, welcomed Mini Kahlon as the newest member of its Board of Directors. Regarding her commitment to Babson’s success, Mini expressed, “I believe the space Babson is moving into has significant potential to move the cost and experience curves, and is essential to the vision of delivering healthcare where we live, work, eat, and play.”

Maninder “Mini” Kahlon is Vice Dean for the Health Ecosystem at the UT Dell Medical School, which she helped to launch. Preceding this role, Mini served as Chief Information Officer and Executive Director for UCSF’s Clinical and Translational Science Institute. Focused on advancing healthcare innovation, Dr. Kahlon has served as Vice Chair of MedTech Innovation for the Austin Chamber of Commerce Board of Directors, Founding Co-Chair of the Austin Healthcare Council, and, as of 2019, Executive Director of Factor Health, a program that builds new businesses to address the broader social and behavioral drivers of health. Dr. Kahlon graduated from Bryn Mawr College and earned a Ph.D. in Neuroscience from the University of California, San Francisco.

Babson Diagnostics Featured in Capital City Innovation Annual Report

AUSTIN, TEXAS, March 11, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, was featured today in Capital City Innovation's 2018 Annual Review. Capital City Innovation is a 501(c)(3) nonprofit focused on cultivating collaboration and growth in Austin's Innovation District, the thriving downtown area that includes UT Austin and Dell Seton Medical Center. In its annual review, Capital City Innovation celebrated Babson Diagnostics as the first graduate of WorkSpaces @ Texas Health CoLab, an Innovation District incubator at UT Austin's Dell Medical School. This graduation is not only a success for the Babson Diagnostics team, who are now moving into their first clinical laboratory, but also for WorkSpaces and the Innovation District as a whole—a signal that healthcare innovation in Austin is flourishing.

The Capital City Innovation annual report is available at: https://www.capitalcityinnovation.org/s/Austin-innovation-district-annual-review-2018.pdf.

Babson Diagnostics hires Jim Donnelly as Chief Scientific Officer & VP Laboratory Operations

AUSTIN, TEXAS, November 5, 2018—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, has hired Jim Donnelly as its Chief Scientific Officer and Vice President of Laboratory Operations.  Jim will be responsible for the company’s clinical laboratory operations and R&D.

Jim is an accomplished scientific officer in the diagnostics industry.  Jim worked at Siemens Healthineers’ Diagnostics division from 2007-2016, where he served as Chief Scientific Officer and Global VP for the division’s Medical, Clinical, Scientific, and Statistical Affairs groups.  He served as EVP Regulatory and Clinical Affairs for Quotient Limited from 2016-2018.

Prior to working in the IVD industry, Jim was an accomplished laboratory director and academic researcher.  Jim was Associate Professor of Pathology at NYU School of Medicine and Associate Director of Laboratory Medicine and Pathology at New York City Health and Hospitals Corporation.  In New York City, he was the Medical Director for multiple clinical pathology disciplines and CLIA high complexity laboratories across Manhattan and the Bronx.

Jim completed his Ph.D. in Pharmacology and Biochemistry at The George Washington University and his MBA from the University of Ottawa.  He holds his Diplomate, Clinical Chemistry, American Board of Clinical Chemists and is a Fellow of the US National Academy of Clinical Biochemistry and the Canadian Academy of Clinical Biochemistry.

Babson Diagnostics Secures $3.5 Million in Series A Financing from Prism Ventures

AUSTIN, TEXAS, October 19, 2018—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, secured $3.5 million in Series A financing on October 4 from Prism Ventures, a New York-based advisory and investment firm specializing in life sciences.

Babson Diagnostics is developing a solution that enables retail stores to collect capillary blood at the pharmacy counter for a broad range of routine blood tests. The solution will enable consumers to get laboratory-grade bloodwork done at their trusted local pharmacy—with a short wait time, a fraction of the blood volume, and no hypodermic needle. The solution will enable retailers to expand their healthcare portfolio to include routine blood testing using their existing pharmacy staff and operations. Babson’s approach will accelerate the shift of healthcare services toward retail settings, helping to improve the consumer experience, increase access to preventive medicine, and make healthcare more affordable.

Prism Ventures has been involved in the formation, financing, and management of eight medical technology companies, including SIGA Technologies, Assertio Therapeutics, and Lev Pharmaceuticals. Prism Ventures executives Judson Cooper and Joshua Schein will join Babson Diagnostics’ Board of Directors.

Babson Diagnostics (www.babsondx.com) will use a portion of the financing to implement its high-throughput microsample laboratory in Austin, Texas. The laboratory will initially serve retail locations in the company’s home markets of Austin, San Antonio, Dallas, and Houston. Babson is currently hiring team members in Austin in business development, administrative, and clinical laboratory fields, including medical technologists, lab managers, and lab technicians. For more information about career opportunities, email jobs@babsondx.com.

Babson Diagnostics relocated from New York to Austin in 2017 after completing a nationwide city search. Babson selected Austin as its headquarters location based on its booming economy, vibrant entrepreneurial ecosystem, and commitment to healthcare innovation via the UT Dell Medical School and Innovation Zone. “Babson Diagnostics’ expansion further reinforces Austin’s growth as a tech, health, and diagnostics hub,” said Charisse Bodisch, SVP Economic Development, Opportunity Austin / Greater Austin Chamber of Commerce. “Opportunity Austin is proud to welcome the development of Babson Diagnostics’ new laboratory and their investment in our region along with the creation of new jobs in the life sciences.”